Drug news
Jardiance plus metformin filed with FDA for T2D-Eli Lilly/Boehringer
The FDA has accepted the filing of a New Drug Application (NDA) for Jardiance (empagliflozin) plus immediate-release metformin hydrochloride fixed-dose combination, from Boehringer and Eli Lilly, which is an investigational compound being studied for the treatment of adults with Type 2 Diabetes (T2D). The filing includes data from multiple clinical trials examining the co-administration of empagliflozin and metformin in the treatment of 4,740 adults with T2D.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.